PT-141: A Complete Guide to Mechanism, Dosing, and Protocols

Section 1

Mechanism of Action

PT-141 is a melanocortin agonist. What makes it distinctive is that it acts centrally, on melanocortin receptors in the nervous system that govern desire and arousal, rather than on the vascular system. That central mechanism is why it is studied for desire and arousal, not just physical function, and why it applies to both sexes.

Central, not vascular

Blood-flow medications act on the vascular system to enable physical function. PT-141 takes a different route entirely, working in the brain on the pathways involved in arousal and desire. This is the core conceptual difference.

Applies to both sexes

Because the mechanism is central rather than dependent on blood flow, PT-141 has been studied in both men and women. The FDA-approved version (Vyleesi) is specifically for women, which underlines that the effect is about desire and arousal broadly.

Desire, not just function

The target is libido and arousal that begins with desire, a different goal from blood-flow medications that address physical capability alone.

Section 3

Dosing Protocols

As-needed protocol

• Used as needed, typically a few hours before intimacy, subcutaneous
• Start with a conservative dose to gauge tolerance, since nausea is dose-related
• Settle on the lowest dose that works, used occasionally rather than frequently

Unit math (10mg vial reconstituted with 2ml BAC water)

10mg / 2ml = 5mg per ml = 5,000mcg per ml. On a 100u insulin syringe (1ml = 100u):

• 1mg dose = 20 units
• 0.5mg starter dose = 10 units

Always measure in units on an insulin syringe, never in mL by eye. Starting low (for example the 10-unit starter) is the best way to manage nausea. See the reconstitution guide.

Section 5

Side Effects: What to Expect

Commonly reported

• Nausea: the most common effect, strongly dose-related. Starting low reduces it substantially.
• Facial flushing: common shortly after a dose.
• Headache: temporary.
• Mild skin darkening: a melanocortin-pathway effect, usually temporary.

The honest framing on safety

PT-141 can transiently raise blood pressure, so people with uncontrolled high blood pressure or cardiovascular conditions should not use it without medical guidance. Because nausea is the main complaint and it is dose-related, the single most effective safety step is starting at a low dose.

Section 7

Contraindications and Cautions

• Uncontrolled high blood pressure or cardiovascular conditions: do not use without medical guidance, given the transient blood-pressure effect
• Pregnancy or breastfeeding: avoid
• A diagnosed sexual-health condition: see your physician rather than self-treating
• Any serious medical condition or prescription regimen: consult your physician before starting

Peptara supplies research-grade PT-141 for research use, distinct from the approved pharmaceutical.

Section 9

Storage and Reconstitution

The lyophilized vial is stable at room temperature before reconstitution. Avoid direct sunlight and heat. For longer storage, refrigerate. Do not freeze the lyophilized powder.

Once reconstituted with bacteriostatic water, store refrigerated at 2-8 degrees C and use within about 30 days. Inspect before each draw: the solution should be clear. Discard if cloudy or discolored.

1. Wipe the vial top with an alcohol swab.
2. Draw 2ml of bacteriostatic water into a syringe.
3. Inject the BAC water slowly down the inside wall of the vial, not directly onto the powder.
4. Swirl gently in your palm. Do not shake.
5. Wait for the powder to fully dissolve and confirm the solution is clear before drawing your dose.

See the Peptara reconstitution guide for an interactive calculator and walkthrough.